The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? - Test2 - elhamkhani - TriplyDB

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

http://www.wikidata.org/entity/Q26768696

about

Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGFβ signaling in the mouse retina

P2860

Q58794337-6F7F9738-A33D-4712-8811-96F634B644A4

P2860

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

http://www.wikidata.org/entity/Q26768696

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@ast

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@en

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@nl

type

label

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@ast

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@en

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@nl

prefLabel

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@ast

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@en

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@nl

P1433

Q26768696-EA12F1AE-AE5B-46BC-AA00-E0911D103DE2

P1476

Q26768696-04F86ABA-5A4F-43E7-A91A-07AD2065BB6E

P2093

Q26768696-5D41F23B-352E-4ADE-8886-CDF3D961D9AA

P275

Q26768696-A0DE4592-AC5F-49E1-BE5F-B0C6A23068D9

P2860

Q26768696-017CDC24-FC48-41FC-A5F8-AAF7C84A4993

Q26768696-029E2F60-1544-40C1-8989-708659596C6A

Q26768696-08C19D8B-7B3B-431C-9018-338B4FFC4B26

Q26768696-0944C38C-51B1-4C94-865D-5091211863D2

Q26768696-09EFEE72-E7CA-44C2-90E1-3CDB272E65A4

Q26768696-0B7E3F85-7D0C-42C6-9D57-D066296C4A4B

Q26768696-0D21ABC5-D50E-4FD2-9B7C-9A8DEEA6C5A3

Q26768696-0D439FF2-D59C-485D-AE57-AE51F88A3CE0

Q26768696-0F4836A2-46AE-462F-9B7A-88315C216E3D

Q26768696-14CCF7B7-2FEB-4B35-87C7-6E850E83D48E

P2888

Q26768696-403C911F-325B-4A46-9D3F-04055B8A007B

P304

Q26768696-9514ADEC-BE69-4A33-B09D-0331ECD29246

P31

Q26768696-BA8F5D62-8CCB-46E4-A45E-4CDED135796E

Q26768696-BEF50573-137E-499A-B1B5-A1F9CBEAAF19

P356

Q26768696-85E77F96-B652-4E16-B9C9-0E7533663D2F

P407

Q26768696-787F35CD-7FB8-4767-B159-0DC65B5F9030

P433

Q26768696-65E4BCF9-26C7-491D-9AB1-AA579C32099B

P478

Q26768696-56925928-F37E-4AF0-92B6-87DA3E32CF81

P577

Q26768696-727E9D0C-10BF-43B5-BCE6-75FCCCA58B2C

Q26768696-A2FF5397-8F5A-441D-81D4-B013335A2DE2

P5875

Q26768696-4F02B8DC-9CAD-496C-ABC5-8C92D9AC8183

P6179

Q26768696-19D84F4D-B4CF-4D40-89A5-B8F0146FCF89

P698

Q26768696-4800A830-0F52-4188-AE13-48D05F9AD76D

P921

Q26768696-2BFE8A3E-6B54-40F3-80E8-6029F2EBA123

Q26768696-99B09098-4C9C-4C49-95E7-8ADC44D90C17

Q26768696-C991FB14-7ACB-4652-8F60-6CA1E8EC2BEA

P932

Q26768696-9FF21593-4235-45EC-A6B6-1D7EDA1809EB

P356

S40256-016-0165-4

P1433

American journal of cardiovascular drugs

P1476

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

@en

P2093

Csaba András Dézsi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Adiponectin and adiponectin receptors

Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence.

Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.

P2888

s40256-016-0165-4

P304

255-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-016-0165-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297002677

http://www.w3.org/2001/XMLSchema#string

P6179

1032625911

http://www.w3.org/2001/XMLSchema#string

P698

26940560

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

polycyclic compound

P932

4947116

http://www.w3.org/2001/XMLSchema#string